Swedish company Biora AB says it has received marketing approval for itsperiodontal product Emdogain (amelogenin) in South Africa. It also announced that it has signed a five-year research agreement with Professor Lindhe of the University of Gothenburg in Sweden. Emdogain, which is applied in gel form on the tooth-root surface during periodontal flap surgery, promotes the regain of tooth-supporting tissues and reattachment of the tooth. The product is already sold in 11 countries around the world. It was launched in the USA earlier this year (Marketletter April 28).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze